↓ Skip to main content

A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML

Overview of attention for article published in Frontiers in oncology, October 2020
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
8 Mendeley